ATE530667T1 - Kcnn3 als diagnostisches und therapeutisches target für alzheimer-krankheit - Google Patents
Kcnn3 als diagnostisches und therapeutisches target für alzheimer-krankheitInfo
- Publication number
- ATE530667T1 ATE530667T1 AT06763326T AT06763326T ATE530667T1 AT E530667 T1 ATE530667 T1 AT E530667T1 AT 06763326 T AT06763326 T AT 06763326T AT 06763326 T AT06763326 T AT 06763326T AT E530667 T1 ATE530667 T1 AT E530667T1
- Authority
- AT
- Austria
- Prior art keywords
- disease
- alzheimer
- kcnn3
- diagnostic
- therapeutic target
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 6
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 101001026232 Homo sapiens Small conductance calcium-activated potassium channel protein 3 Proteins 0.000 title 1
- 102100037442 Small conductance calcium-activated potassium channel protein 3 Human genes 0.000 title 1
- 238000000034 method Methods 0.000 abstract 3
- 101150024043 KCNN3 gene Proteins 0.000 abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 230000008482 dysregulation Effects 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68507205P | 2005-05-27 | 2005-05-27 | |
| EP05104552 | 2005-05-27 | ||
| PCT/EP2006/062667 WO2006125830A2 (en) | 2005-05-27 | 2006-05-29 | Kcnn3 as diagnostic and therapeutic target for neurodegenerative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE530667T1 true ATE530667T1 (de) | 2011-11-15 |
Family
ID=35457791
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06763326T ATE530667T1 (de) | 2005-05-27 | 2006-05-29 | Kcnn3 als diagnostisches und therapeutisches target für alzheimer-krankheit |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20090172827A1 (de) |
| EP (1) | EP1888783B1 (de) |
| JP (1) | JP2008545402A (de) |
| AT (1) | ATE530667T1 (de) |
| WO (1) | WO2006125830A2 (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| DK1976877T4 (en) | 2005-11-30 | 2017-01-16 | Abbvie Inc | Monoclonal antibodies to amyloid beta protein and uses thereof |
| CA2628703C (en) | 2005-11-30 | 2019-10-29 | Abbott Laboratories | Anti-a.beta. globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| WO2008104386A2 (en) | 2007-02-27 | 2008-09-04 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
| FR2929292A1 (fr) * | 2008-03-28 | 2009-10-02 | Exonhit Therapeutics S A Sa | Procede et methodes de diagnostic de la maladie d'alzheimer |
| HUP0900431A2 (en) * | 2009-07-10 | 2011-01-28 | Cryo Innovation Kft | Sample imaging system and pocedure for transmitting imager of cells or tissues located in breeder space towards a data processing device |
| CN104744591B (zh) | 2010-04-15 | 2022-09-27 | Abbvie德国有限责任两合公司 | β淀粉样蛋白结合蛋白 |
| WO2012024187A1 (en) | 2010-08-14 | 2012-02-23 | Abbott Laboratories | Amyloid-beta binding proteins |
| PH12014500763A1 (en) * | 2011-10-04 | 2014-05-12 | Psychnostics Llc | Methods for diagnosing and identifying modulators of membrane potentials in bipolar disorder and attention deficit hyperactivity disorder |
| EP3953458A1 (de) * | 2019-04-12 | 2022-02-16 | Ultragenyx Pharmaceutical Inc. | Gentechnisch veränderte produktionszelllinien und verfahren zu deren herstellung und verwendung |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4438391C2 (de) | 1994-10-27 | 1997-07-03 | Evotec Biosystems Gmbh | Vorrichtung zur Bestimmung stoffspezifischer Parameter eines oder weniger Moleküle mittels Korrelations-Spektroskopie |
| DE19709348C2 (de) | 1996-05-29 | 1999-07-01 | Schubert Walter Dr Md | Automatisches Multi-Epitop-Ligand-Kartierungsverfahren |
| EP0836090A1 (de) | 1996-10-12 | 1998-04-15 | Evotec BioSystems GmbH | Probenanalyseverfahren durch Bestimmung der spezifischen Helligkeitsverteilung von Teilchen |
| DE19649048C1 (de) | 1996-11-27 | 1998-04-09 | Evotec Biosystems Gmbh | Verfahren zur Unterscheidung oder Erfassung von Partikeln in einer Probe durch Identifizierung von Signalabschnitten zeitaufgelöster, optischer Rohsignale aus der Probe auf Basis von Einzelphotonendetektion |
| AU742407B2 (en) * | 1997-07-15 | 2002-01-03 | Regents Of The University Of California, The | Isolated DNA encoding human calcium activated potassium channel |
| EP0945718A1 (de) | 1998-03-21 | 1999-09-29 | Evotec BioSystems AG | Ein Verfahren zur Probencharakterisierung durch Bestimmung einer Funktion mindestens einer spezifischen Eigenschaft von Einheiten der Probe |
| EP1042664B1 (de) | 1997-12-23 | 2001-10-31 | Evotec BioSystems AG | Verfahren zum nachweis von reaktionen mittels koinzidenzanalyse |
| DK1157267T3 (en) | 1999-03-03 | 2017-01-23 | Olympus Corp | Method for fluorescence binding assay |
| JP3559525B2 (ja) | 1999-04-29 | 2004-09-02 | エボテック オーアーイー アクチェンゲゼルシャフト | 生成関数を用いて蛍光分子又は他の粒子を特徴付ける方法 |
| ATE264499T1 (de) | 2000-02-10 | 2004-04-15 | Evotec Ag | Fluoreszenzintensitätsanalyse unter verwendung einer vielzahl von verteilungen: konkurrierende bestimmung von diffusionszeiten und molekularer helligkeit |
| US6690463B2 (en) | 2000-02-10 | 2004-02-10 | Evotec Biosystems Ag | Fluorescence intensity and lifetime distribution analysis |
| DE10030798A1 (de) | 2000-06-29 | 2002-01-10 | Evotec Analytical Sys Gmbh | Kompetitives Assay-Verfahren |
| AU2003260460A1 (en) | 2002-08-28 | 2004-03-19 | Evotec Neurosciences Gmbh | Diagnostic and therapeutic use of foap-13 polynucleotides and polypeptides for neurodegenerative diseases |
| US20050010967A1 (en) * | 2003-02-28 | 2005-01-13 | The Regents Of The University Of California | SK3-1B GFP transgenic mouse model for spinocerebellar ataxia and hyperexcitable behavior |
-
2006
- 2006-05-29 AT AT06763326T patent/ATE530667T1/de not_active IP Right Cessation
- 2006-05-29 EP EP06763326A patent/EP1888783B1/de not_active Not-in-force
- 2006-05-29 JP JP2008512849A patent/JP2008545402A/ja not_active Withdrawn
- 2006-05-29 WO PCT/EP2006/062667 patent/WO2006125830A2/en not_active Ceased
- 2006-05-29 US US11/920,734 patent/US20090172827A1/en not_active Abandoned
-
2010
- 2010-06-02 US US12/792,611 patent/US20110010780A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20090172827A1 (en) | 2009-07-02 |
| WO2006125830A3 (en) | 2007-02-15 |
| EP1888783A2 (de) | 2008-02-20 |
| US20110010780A1 (en) | 2011-01-13 |
| EP1888783B1 (de) | 2011-10-26 |
| JP2008545402A (ja) | 2008-12-18 |
| WO2006125830A2 (en) | 2006-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2005108999A3 (en) | Diagnostic and therapeutic use of kcnj6 for alzheimer’s disease | |
| EA200700083A1 (ru) | Антитела, направленные против бета-амилоидного пептида, и способы их применения | |
| WO2004065576A3 (en) | Methods and compositions for the treatment of urological disorder using differential expressed polypeptides | |
| ATE530667T1 (de) | Kcnn3 als diagnostisches und therapeutisches target für alzheimer-krankheit | |
| WO2004070388A8 (en) | Diagnostic and therapeutic use of scn2b protein for neurodegenerative diseases | |
| ATE495269T1 (de) | Adarb2 proteine als diagnostische und therapeutische targets für neurodegenerative erkrankungen | |
| WO2004003563A3 (en) | Diagnostic and therapeutic use of ensadin-0581 gene and protein for neurodegenerative diseases | |
| ATE449964T1 (de) | DIAGNOSTISCHE VERWENDUNG VON ßENSADIN-0477ß FÜR NEURODEGENERATIVE ERKRANKUNGEN | |
| WO2002046767A3 (en) | Diagnosis and treatment of alzheimer's disease | |
| ATE534751T1 (de) | Verwendung von prkx zur diagnose und therapie von alzheimer krankheit | |
| WO2004001422A3 (en) | Diagnostic and therapeutic use of ras-gtpase-activating sh3-domain-binding protein 2 (g3bp2) for neurodegenerative diseases | |
| WO2005030947A3 (en) | Diagnostic and therapeutic use of a sulfotransferase for neurodegenerative diseases | |
| ATE458834T1 (de) | Diagnostische und therapeutische verwendung des mal2-gens und proteins bei neurodegenerativen krankheiten | |
| ATE464567T1 (de) | Diagnostische und therapeutische verwendung von f-box-proteinen bei morbus alzheimer und verwandten neurodegenerativen erkrankungen | |
| WO2004038411A3 (en) | Diagnostic and therapeutic use of ensadin-0289 gene and protein for neurodegenerative diseases | |
| ATE495271T1 (de) | Zusammensetzungen und verfahren zum nachweis von störungen in verbindung mit histamin | |
| ATE316657T1 (de) | Diagnostische und therapeutische verwendung des caps | |
| WO2006131562A3 (en) | Diagnostic and therapeutic target cdc2l6 gene and proteins for neurodegenerative diseases | |
| DK1379882T3 (da) | Diagnostisk og terapeutisk anvendelse af et nuclearbegrænset protein til Alzheimers syge og beslægtede neurodegenerative forstyrrelser | |
| ATE365175T1 (de) | Diagnostische und therapeutische verwendung von humanen maguinproteinen und nukleinsäuren bei neurodegenerativen krankheiten | |
| WO2005071418A3 (en) | Diagnostic and therapeutic use of the human dax- 1 gene and protein for neurodegenerative diseases | |
| WO2003087403A3 (en) | Diagnostic and therapeutic use of a golgi protein for neurodegenerative diseases | |
| WO2005059562A3 (en) | Diagnostic and therapeutic use of the human hif3alpha gene and proteins for neurodegenerative diseases | |
| WO2003100092A3 (en) | Diagnostic and therapeutic use of cyp11a1 for neurodegenerative diseases | |
| WO2004020665A3 (en) | Diagnostic and therapeutic use of foap-13 polynucleotides and polypeptides for neurodegenerative diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |